小细胞外囊泡:一种用于神经退行性疾病的新型药物递送系统
Renjie Pan1,2, Dongdong Chen1,2, Lanlan Hou1,2
1First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi, China.
Frontiers in aging neuroscience
|July 5, 2023
概括
小型细胞外囊泡 (sEVs) 显示出作为神经退行性疾病 (NDs) 药物递送系统的前景. 这些囊泡可以克服血脑屏障,为治疗阿尔茨海默症等疾病提供潜在的解决方案.
科学领域:
- 神经科学是一个神经科学.
- 生物技术是生物技术.
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经退行性疾病 (NDs) 由于晚期检测和血脑屏障 (BBB) 存在重大治疗挑战.
- 无病症的有效治疗方法有限,造成了巨大的社会和财务负担.
- BBB限制了药物和治疗分子向大脑的输送.
研究的目的:
- 审查小细胞外囊泡 (sEV) 作为神经退行性疾病的药物递送系统 (DDS) 的治疗应用.
- 讨论使用sEV用于针对大脑的药物输送的挑战和障碍.
- 在神经退行性疾病中探索基于sEV的治疗方法的未来研究方向.
主要方法:
- 对神经退行性疾病治疗中SEVs现有研究的文献综述.
- 对sEV属性的分析与BBB的药物输送有关.
- 讨论基于sEV的DDS的当前局限性和潜在解决方案.
主要成果:
- 小型细胞外囊泡 (sEVs) 显示出作为神经退行性疾病的药物递送系统 (DDS) 的巨大潜力.
- sEV具有有利的特性,包括低毒性,高生物相容性,稳定性和穿越BBB的能力.
- 对于阿尔茨海默病,帕金森病和亨廷顿病的治疗应用正在探索.
结论:
- 在治疗神经退行性疾病方面,sEVs代表了一种有希望的治疗策略,可以克服BBB的局限性.
- 需要进一步的研究来解决当前的障碍,并优化基于sEV的DDS用于临床应用.
- sEVs提供了一个多功能平台,可以有针对性地向大脑输送治疗剂.
相关概念视频
01:36Overview of Exosomes
2.8K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.8K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
350
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
350
02:30siRNA - Small Interfering RNAs
16.9K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.9K
01:26Fusion of Secretory Vesicles with the Plasma Membrane
11.1K
Proteins and neurotransmitters in secretory vesicles can be released from a cell upon vesicle docking, priming, and fusion with the plasma membrane. Vesicles are docked and primed in preparation for the quick exocytosis of their contents in response to a stimulus. The fusion process is mainly carried out by a SNAP Receptor or SNARE complex, consisting of synaptobrevin, syntaxin-1, and SNAP-25.
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
11.1K